Improving life for cancer patients through transformative drugs




Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Read more

Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of study

Read more

Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.